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3,2'-Dimethyl-4-aminobiphenyl (DMAB) is a potent carcinogenic aromatic amine which demonstrates multiorgan tropism in rats. Using polyclonal
antibodies against DMAB-DNA adducts, an immunohistochemical procedure as well as an ELISA were applied to investigate the relationship
between DMAB-DNA adduct formation and tumorigenicity. Dose-related nuclear staining was observed 24 hr after application of the carcinogen but
specificity in terms of sites of tumor development was lacking. No observable decrease in staining intensity was evident in most organs by 168 hr
after administration of DMAB. Specific DNA lesions which could be responsible for carcinogenesis were not detected by the 32P-postlabeling
method. The tumorigenic response of the ventral prostate in five strains of rats was roughly paralleled by DMAB-DNA adduct levels generated in the
tissue. Strong enhancement of bladder tumor development by combined administration of the antioxidants, butylated hydroxyanisole, or butylated
hydroxytoluene, with DMAB, was well correlated with an increase in DNA adducts. Our findings so far suggest that DNA adduct formation itself
does not determine the carcinogenic organotropism of DMAB. Other factors (including cell proliferation and promotion by exogenous agents) may
play important additional roles. For individual target organs or tissues, however, there seems to be a correlation between adduct levels and carcino-
genic potential. - Environ Health Perspect 102(Suppl 6):167-172 (1994)
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Introduction
The process ofchemically induced carcino-
genesis generally is divided conceptually
into initiation and promotion stages. In the
initiation stage, reactive carcinogen and/or
metabolite(s) covalently bind to DNA in
target tissues to form DNA adducts. These
modifications lead to development ofDNA
damage, resulting in the production of ini-
tiated cells. These cells are then susceptible
to promotional stimuli, which leads to
tumor formation. The initiation event is
believed to be an irreversible process and
therefore a key point in chemical carcino-
genesis.
3,2'-Dimethyl-4-aminobiphenyl
(DMAB) is a potent multiorgan carcino-
genic aromatic amine that targets the
colon, Zymbal gland, preputial gland, uri-
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nary bladder, prostate, pancreas, and sub-
cutis (1-5). Tissue specificity is also exhib-
ited within the prostate complex (4-6).
The seminal vesicles are also targeted and
develop atypical hyperplasias. Clarification
of the relationships between the carcino-
genicity of DMAB and DNA damage in
specific organs or tissues is an important
goal in understanding mechanism(s) of
chemical carcinogenesis. Specific antibodies
have recently been developed against such
carcinogen-DNA adducts and used for the
sensitive detection of adduct formation in
tissues (7-9). An immunohistochemical
approach using such specific antibodies
makes possible the precise localization of
adduct formation at the cellular level
(10,11).
We have developed polyclonal antibodies
specific for DMAB-DNA adducts. In this
article, we describe the immunohistochem-
ically visualized distribution of DNA
adducts, and present a quantitative com-
parison of adduct levels in relation to
tumor response.
Immunohistochemical Demonstration
ofDMAB-DNAAdduct
Polyclonal antibody specific for DMAB-
modified DNA (DMAB-DNA) was raised
in rabbits as described previously (12). The
antibody recognizes DNA modified with
N-OH-DMAB and N-hydroxy-4-amino-
biphenyl, but not unmodified, 2-acetyl-
aminofluorene- or 4-nitroquinoline
1-oxide-modified DNA, or free amino-
biphenyl and DMAB derivatives. Relative
affinities of the antibody were given previ-
ously (12).
Male F344 rats (Charles River, Japan),
9 weeks old, received DMAB (>98%
purity) dissolved in 0.5 ml ofcorn oil by sc
injection at various doses and 24 hr later all
animals were killed and autopsied. The
influence oforchiectomy and chemical cas-
tration with estrogen on adduct formation
was also studied. Organs or tissues were
fixed in cold acetone for 1 week and
processed routinely for preparation of
paraffin sections. Adducts in paraffin sec-
tions were visualized immunohistochemi-
cally as described previously (13).
Tables 1 and 2 summarize data for tissue
or organ specificity ofcarcinogenic action
and dose-related staining intensities in rats
given sc injections of 200, 50, and 10 mg
DMAB/kg bw. Dose-dependent staining
was observed with only very weak intensity
at a level of 10 mg. At a dose of 200
mg/kg, almost all organs examined demon-
strated positive staining, at least to a certain
degree, regardless oftheir DMAB-carcino-
genic target status (Figure 1). In the male
accessory sex organs, strong staining was
observed in the ventral and lateral prostate
lobes; the seminal vesicles exhibited promi-
nent nuclear staining, lighter staining being
evident in the dorsal and anterior (coagu-
lating gland) lobes (Figure 2). A positive
reaction was found for both the acinar and
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ductal epithelial cells of the prostate.
Target sites of DMAB-carcinogenicity are
the ventral prostate and seminal vesicles and
other target organs, including the urinary
bladder, colon, preputial glands, Zymbal
glands, sebaceous glands, and pancreas. All
exhibited positive staining.
However, nontarget organs such as the
kidney, lung, brain, and salivary glands also
exhibited positive staining. The positive
sites in the liver were the hepatocytes and
sinusoidal endothelial cells distributed uni-
formly throughout the lobules and those in
the kidney were the distal and collecting
tubule cells. Positive binding in the salivary
glands was located in the acinar cells ofthe
submandibular gland and the duct epithe-
lial cells ofthe sublingual glands. A weak
positive staining was also found in primary
spermatocytes of the testis and accessory
glands ofthe skin. In the brain, glia cells
and choliod plexus were positive, while
neurocytes were negative. Heart muscle
proved negative. Investigation of DMAB-
DNA adduct persistence continued until
Table 1. Immunohistochemical localization of DMAB-
DNA adducts in rats 24 hr after a single sc injection of
DMAB atvarious doses.
Carcino- Dose of DMAB, mg/kg bw
Organ genicitya 200 50 10 0
Prostate: Ventral + ++b +
Lateral - ++ + +
Dorsal - + + +
Anterior - + ± -/+
Seminal vesicles ± ++ ++ +1-
Bladder + ++ + +/-
Colon ++ +/++ +/+ ±/-
Ileum + +/-W)C ±(+) (+) -
Preputial glands ++ ++/+ + +/-
Sebaceous glands ++ ++ NE NE
Pancreas ± ++ + +
Liver ± ++/+ + +
Testis - ++ NE NE
Kidney - + + +
NE, not examined. 'Carcinogenicity evaluated in our
previous papers (4,5,7,16,23). bStaining intensity: -,
negative; ±, trace to weakly positive; +, positive; ++,
strongly positive. Cln parentheses are staining intensi-
ties of interstitial cells ofthe crypts.
Table 2. Persistence of nuclear staining of DMAB-DNA
adducts in rats given a single injection of DMAB.
Carcino- Hours after DMAB injectiona
Organ genicityb 24 72 168
Prostate: Ventral + HC ++ ++
Lateral _d ++ + +
Dorsal -d + + +
Anterior d + + +
Seminal vesicles ++ + +
Liver ++/+ + +
Pancreas ± ++ + +
Colon ++ +/++
Ileum + +/1-+) ±(+) -+)
Bladder + ++ + +/±
Preputial glands ++ ++/+ + +/-
Zymbal glands + +/- NE
Sebaceous glands + ++ NE +
Kidney - + + +
Salivary glands - ++ NE +
Lung - + NE +
Heart - - NE -
Brain - +,++e NE +/++
Epidermis - - NE -
NE, not examined. aThe dose of DMAB was 100 or 200
mg/kg bw. bCarcinogenicity evaluated in our previous
papers (4,5,7,16,23). Cln parentheses are staining
intensities of interstitial cells of the crypts. dTumors
could be induced by administration of DMAB and then
testosterone propionate. @Glia cell/ependymal cell.
Figure 1.Variation in staining in different organs. DMABwas given ata dose of200 mg/kg bw. (A)colon,(B) bladder,
(C) liver, and (D) kidney.
AWgNJ'1
Figure 2. Variation in staining intensity in the prostate and seminal vesicles. (A) ventral lobe, (B) lateral lobe,
(C) anterior lobe, (D) dorsal lobe, and (E) seminal vesicles.
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168 hr after the administration of DMAB
revealed no clear changes in staining inten-
sity in organs other than the urinary blad-
der, colon, ileum, and duct epithelium of
the preputial glands (Table 2).
Orchiectomy caused severe atrophy of
all parts ofthe accessory sex organs associ-
ated with a marked to moderate decrease in
staining intensity. Mild to moderate atrophy
induced by chemical castration with
ethinyl estradiol was accompanied by mod-
erate to slight decrease in staining intensity.
Strain Differences in Prostatic
Carcinogenesis andAdductFormation
Tumorigenic response to DMAB in the
prostates of F344, ACI, Lewis, CD, and
Wistar strain rats was examined in relation
to adduct formation (14). Rats received
DMAB sc at a dose of 50 mg/kg bw 10
times, once every other week. The experi-
ment was terminated at week 60. The final
survival rates were 44, 28, 46, 27, and 0%
in F344, ACI, Lewis, CD, and Wistar rats,
respectively. All Wistar strain rats died by
week 50. Carcinomas of the ventral
prostate were found in 46, 50, 5, 0, and
0% ofF344, ACI, Lewis, CD, and Wistar
strain animals, respectively (Table 3).
The amounts of DMAB adducts in
DNA samples isolated from the prostate
and liver of the five strains of rats 24 hr
after administration ofa single sc injection
of DMAB 200 mg/kg bw were quantita-
tively analyzed using ELISA. The results
were calculated as numbers ofadducts per
106 nucleotides (Table 3). Ventral prostate
values for the 5 strains ranged from 2.75
adducts per 106 for F344 and Wistar ani-
mals, to 1.00 adduct per 106 nucleotides in
Lewis rats. The dorso-lateral lobe levels
were about 45 to 70% ofthose in the ven-
Table 3. Incidences (%) of preneoplastic and neoplastic lesions of the ventral prostate in five strains of rats (F344,
ACI/N, Lewis, CD, Wistar) and their relation to DNA adductformation.
Prostate lesionsa DNA adductsb
Strain Number of rats Atypical hyperplasia Carcinoma Ventral prostate Liver
F344 24 17 (71) 11 (46) 2.75 3.66
ACI/N 24 19 (79) 11 (50) 2.22 3.56
Lewis 24 7 (32) 1 (5) 1.00 2.22
CD 13 0 0 1.47 2.22
Wistar 7 1 (14) 0 2.75 3.50
"All lesions were found in the ventral lobe except for one carcinoma located in the dorso-lateral lobe of a CD rat.
bData obtained from an independent experiment and expressed as adducts/106 nucleotides.
tral lobes, depending on the strain. With
regard to the liver, F344, ACI, and Wistar
strain animals demonstrated similar num-
bers ofadducts (about 1.6 times the respec-
tive values for Lewis and CD). Thus,
ventral tumor yield correlated well with
DMAB-DNA adduct formation (except in
the case of Wistar rats which died very
early from nephropathy).
Alteration ofTumorSites inthe
Prostate ComplexbyA mistration
ofTestosterone Propionate after
DMABTreatment
Promotion effects oftestosterone propionate
(TP) on prostate carcinogenesis were inves-
tigated in F344 rats given DMAB. One
group of F344 rats received sc DMAB
injections at a dose of 50 mg/kg bw at 2-
week intervals for a total of 10 times and
then sc implantations ofTP-containing
silastic tubes for 40 weeks. Prostate carcino-
mas were found in the lateral and anterior
prostate and seminal vesicles, as well as in
the ventral prostate in rats so treated, while
DMAB without subsequent TP adminis-
tration induced only ventral prostate
tumors (Table 4).
Table 5. Incidences of neoplastic and preneoplastic lesions in the urinary bladder and other organs of rats given
DMAB and BHA or BHT.
Incidences oftumors(%) DNAadducts/1 06 nucleotidesa
DMAB + BHA BHT Control
Number of rats 20 20 20 BHA BHT Control
Bladder 18.3 ±0.70b 12.3± 1.2d 6.5± 0.8
Papilloma 15 (75)b 17 (85)b 0
Carcinoma 15 (75)b 14 (70)b 0
Liver 10.0± 0.1 3.5 ± 0.6 21.0 ± 0.2
Hyperplastic foci 8 (40)c 3 (15)c 19 (95)
Pancreas 16.3 ±0.3 13.8 2.8d 18.3 ± 1.3
Acinar cell foci 4 (20) 1 (5)c 9 (45)
Small intestine 1.8± 0.2 3.8 ±0.5 4.7 ±0.4
Adenoma/carcinoma 2 (10) 1 (5) 3 (20) b b
Colon 7.6 ± 0.4 9.6 ± 0.6 12.3 ± 0.5
Adenoma/carcinoma 0 5 (25) 3 (15)
aMeans ± SE of four determinations. bSignificantly different from the corresponding control value at p < 0.001.
CSignificantly different from the corresponding control value at p < 0.01. dSignificantly different from the corre-
sponding control value atp< 0.05.
Table 4. Prostate tumor development in the lateral
and anterior lobes after administration of DMAB and
then testosterone propionate.
No. of
Treatment rats
DMAB 17
DMAB--TP 15
Incidences of prostate tumor(%)
Ventral Lateral Anterior
5 (33.3) 0 0
1 (5.9) 3 (17.6) 5 (29.4)
TP, testosterone propionate.
Modificatdon ofDMABCarcinogenesis
byBHAandBHTandRelationship to
AlterationoftheAdductFormation
Modification of DMAB-multiorgan car-
cinogenesis by simultaneous treatment
with BHA or BHT was studied using male
F344 rats (15). Four-week old animals
were given DMAB (sc injection of 50
mg/kg bw once a week for 10 weeks) dur-
ing administration of BHA (2.0% in diet
for 11 weeks) or BHT (1.0% in diet for 11
weeks). The experiments were terminated
at week 55, at which time the incidences of
urinary papillomas and carcinomas in rats
given DMAB plus BHA or BHT were
more than 70%, whereas no bladder
tumors were evident in animals given
DMAB alone (Table 5). The development
of preneoplastic lesions in the liver and
pancreas, however, was reduced approxi-
mately one half by BHA and BHT. No
modification by BHIA or BHT was evident
for these tumor inductions in other organs.
The urinary bladders ofrats given DMAB
with BHA or BHT had two or three times
the levels of DMAB-DNA adducts in rats
given DMAB alone (Table 5). In contrast,
the amounts ofthe adducts in the livers of
rats given DMAB plus BHA or BHT were
significantly lower than those given DMAB
alone. Suppression ofadduct formation in
the liver by BHT was stronger than by
BHA. Those in the colon were also
decreased by the concomitant treatment
with BHA or BHT.
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Immunohistochemically, the nuclear
staining intensity ofthe urinary bladders of
rats given DMAB plus BHA or BHT was
clearly stronger than that of rats given
DMAB alone. In the livers, however, the
intensities were weaker in the antioxidant
groups. BHT suppressed the formation of
the adducts particularly in the centrilobular
areas, whereas BHA exerted diffuse effects.
Demonstmtion ofSpeificDNALesions
bythe P-Postlab& Method
DMAB-DNA adducts were analyzed by
the 1-butanol extraction method (17).
DNA (10 pg) was digested to 3'-mononu-
cleotides at 370C for 3.5 hr with micrococ-
cal nuclease and spleen phosphodiesterase
as described previously (18). DMAB-DNA
adducts were then extracted with water-sat-
urated 1-butanol from 8-jg samples of
DNA digests according to the method of
Gupta (17), and then 32P-labeled by T4
polynucleotide kinase with 2.0 pM[y-32P]-
ATP (7000 Ci/mmoles) at 37°C for 1 hr.
The labeled solutions were applied to a
PEI-cellulose layer. Adducts were located
by screen-enhanced autoradiography at
-80°C for 2 days. Amount of total
nucleotides were determined as described
previously (17) and adduct levels were cal-
culated from radioactivities ofthe spots for
each adduct divided by the radioactivity for
the total nucleotides (17).
Figure 3 illustrates autoradiograms of
DNA adducts in the prostate complex and
liver of rats exposed to 150 mg/kg of
DMAB 24 hr before sacrifice. The levels
AB
were 37.1, 14.6, 6.8, 15.3, 6.7, and 39.7
adducts per 109 nucleotides in the ventral,
lateral, dorsal, anterior lobes, the seminal
vesicles, and the liver, respectively. Four
spots usually were observed in both the
prostate complex and the liver. The ratios
ofadduct levels ofno. 2 and no. 3 spots to
total adducts were lower in the prostate
complex (about 10%) than the liver (about
30%). There were no clear differences in
the ratio ofeach spot among prostate lobes,
but no. 5 spot could only be clearly
detected in the ventral prostate and not in
other organs.
Discussion
Immunohistochemical staining of DNA-
carcinogen adducts revealed that DMAB
metabolites bind to DNA in a variety of
organs. This approach has the advantage of
allowing localization at the cellular rather
than the tissue or organ levels. However,
observed distribution of adducts did not
obviously correspond to the reported and
observed sites of tumor development in
DMAB-exposed rats. While all target
organs of DMAB examined, including the
colon, small intestine, ventral prostate,
seminal vesicles, preputial gland, urinary
bladder, sebaceous gland, pancreas, and
liver were positive, nontarget organs such
as the kidney, salivary gland, testis, and
anterior, lateral, and dorsal prostate lobes
also demonstrated considerable formation
of DNA adducts. Similar anomalous
findings in nontarget tissues have been
reported earlier (19). Quantitation of
..
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Figure 3. Autoradiograms of DMAB-DNA adducts in the liver and prostate. (A) ventral lobe; (B) lateral lobe;
(C) dorsal lobe; (D) anterior lobe; (E) seminal vesicles and (F) liver. Atotal of five spots can be identified.
adduct levels also did not reveal any direct
correlation with DMAB-organotropism
(12). In addition, persistence of DMAB-
DNA adducts up to 168 hr after the single
carcinogen treatment in the present experi-
ment did not allow an explanation of
organotropism on the basis of differential
repair.
DNA modification through covalent
binding ofcarcinogen(s) is thought to be an
essential step for the activity ofgenotoxic
carcinogens but not in itselfenough to ini-
tiate carcinogenesis. In addition to possible
formation of DNA adduct types that are
nonrelevant to carcinogenesis, a high
efficiency of DNA repair and therefore
inadequate fixation of heritable DNA
lesions also have been suggested as compli-
cating factors. The chemical natures of the
main DNA-DMAB products were
identified by Flammang et al. (20) as N-
(deoxyguanosin-8-yll-DMAB (60-70%),
5-(deoxyguanosin-N -yl)-DMAB (2-3%)
and N-(deoxyadenosin-8-yl)-DMAB
(1-3%). At present, antibodies specific for
individual isolated DNA adducts are not
available, and detection of the forms pri-
marily responsible for carcinogenesis awaits
the development ofsuch analytical tools.
32P-Postlabeling demonstrated five
observable spots, indicating five different
DNA adducts, and although each spot has
not yet been characterized, nos. 1 to 3 seem
to correspond to N-(deoxyguanosin-8-yl)-
DMAB, 5-(deoxyguanosin-N2-yl)-DMAB,
and N-(deoxyadenosin-8-yl)-DMAB,
respectively. Warranting further attention
is spot no. 5 that was detected only in the
ventral lobe and seminal vesicles, which are
susceptible to DMAB carcinogenesis.
Many carcinogenic compounds that
have no effect under normal conditions
induce liver carcinomas when applied during
the period of regenerative cell proliferation
after partial hepatectomy (22). DMAB was
found to induce rat pancreatic tumors
when given at doses necrogenic for the
pancreas (13) and cell proliferation at the
time of carcinogen action is generally
accepted to play an important role in the
initiation of carcinogenesis, presumably via
fixation of heritable DNA lesions.
Accordingly, one might expect develop-
ment ofliver tumors in rats given DMAB
only in association with partial hepatectomy,
since this carcinogen is not particularly
toxic in this organ. Since carcinogenesis is a
multistage process, a second complicating
factor that should be recognized is that
promotion may be required for the devel-
opment ofvisible tumors in organs with
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DMAB-DNA adduct formation that are
normally considered to be nontarget tis-
sues. A good example for this is apparent
from experiment 3. Under normal condi-
tions, DMAB induces prostate tumors only
in the ventral lobe. However, long-term
treatment with TP after DMAB injection
results in tumor development also in the
lateral and anterior prostate and seminal
vesicles.
There is a possibility that the adduct
patterns in different tissues might varywith
single and multiple dosing and indeed our
studies with DMAB have shown that car-
cinogenic response is related to the dosing
schedule (5). The multiorganotropicity of
DMAB carcinogenicity is also dependent
on the strain of rat investigated. With
respect to prostate tumorigenesis, F344 rats
showed a high susceptibility not shared by
other strains. N-OH-DMAB, a proximate
form of DMAB, can be further metabo-
lized by O-acetylation to yield a carcino-
genic form that is capable ofreacting with
nucleic acids (20,23). However, the
prostate tumorigenic response could not be
correlated with the activity of this enzyme
in the ventral lobe (24), suggesting that
prostate-susceptibility to DMAB carcino-
genicity is related to both activation within
the target organ and disposition and excre-
tion patterns of the chemical and/or its
metabolites in the whole body. The
observed differences in the numbers of
DMAB-DNA adducts in the ventral
prostate among the five strains of rats, on
the other hand, did demonstrate a good
correlation between these lesions and the
tumorigenic response, except in the Wistar
rat case, which had a poor survival period.
The very weak staining in atrophied
prostate tissue resulting from orchiectomy
might account for the decreased tumor
response in the prostate under such condi-
tions (21). Loss ofactivating enzyme(s) in
the epithelial cells in this case may be one
of the reasons why DMAB-DNA adduct
formation is decreased.
The striking finding that a simultane-
ous administration ofDMAB with BHA or
BHT strongly enhanced urinary bladder
tumor induction while inhibiting the
appearance ofpreneoplastic lesions in the
liver and pancreas offered direct support
for an adduct role. Thus, quantitative assay
of carcinogen-DNA adduct formation
clearly demonstrated that the amounts of
DMAB-DNA in the urinary bladder, liver,
and pancreas correlated well with the
tumorigenic response; both BHA and
BHT increased levels of DMAB-DNA
adducts in the urinary bladder, but
decreased those in the liver and pancreas. A
discrepancy was observed only for the
colon where a decrease in the amount of
DMAB-DNA adducts was found but no
change in tumor incidence occurred. The
reason might be that although the drop in
DNA adducts in the experimental groups
was statistically significant, it was not low
enough to result in decreased tumor induc-
tion. In fact, no apparent difference in
nuclear staining intensity was present in
the immunohistochemically stained colon
samples.
The mechanisms by which BHA and
BHT modulate DMAB carcinogenesis
seem to be the same as those proposed in
the case ofmodulation of2-AAF carcino-
genesis by BHT (25), i.e., changes in car-
cinogen metabolism resulting in increased
or decreased ultimate carcinogenic species,
because BHA and BHT are inducers of
drug metabolizing enzymes such as
cytochrome P450s, epoxide hydroxylase,
glucuronyltransferase, and glutathione S-
transferase (26). Increased excretion of
glucuronic acid conjugates (27) ofN-OH-
DMAB resulting from an alteration ofliver
metabolism by BHA and BHT could have
played an important role in enhancing uri-
nary bladder carcinogenesis and inhibiting
hepatic carcinogenesis in the present exper-
iment. Another factor that could have
acted in the enhancement ofurinary blad-
der carcinogenesis is increased DNA syn-
thesis in the urinary bladder epithelium
induced by BHA and BHT (28,29).
Therefore, synergistic effects of increased
reactive metabolite(s) of DMAB in the
urine and increased DNA synthesis in the
urothelium are medicated as the mecha-
nism behind strong enhancement of uri-
nary bladder carcinogenesis.
In conclusion, the data regarding initial
formation ofDNA adducts by DMAB and
their persistence suggest that DNA lesions
themselves are not sufficient to explain
tumor induction. Involvement ofother fac-
tors, including cell proliferation and pro-
motion, require further investigation. The
findings on staining differences and BHA-
or BHT-modulation, however, do indicate
that there is a correlation between adduct
levels and carcinogenic potential for indi-
vidual target organs or tissues.
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